The study reports improvements in glycemic control, GLP-1 response and lipid markers with bio-optimised berberine
Hyderabad : Zeus Hygia
Lifesciences, an innovator in nutraceutical solutions, today announced the
publication of a clinical study evaluating Metaberine®, its bio-optimised
berberine formulation developed using proprietary BioSOLVE® Technology.
Published in the International Journal of Clinical Trials, the
randomized, double-blind, placebo-controlled crossover trial found that
Metaberine® at 200 mg per day significantly improved multiple markers of
metabolic health in adults at metabolic risk.
The study evaluated 36 healthy adults with fasting glucose levels of
100-125 mg/dL. Participants received Metaberine® 200 mg or placebo once daily
for 14 days, followed by a seven-day washout period. The findings demonstrated
significant improvements in fasting and postprandial glucose levels, along with
enhanced GLP-1 response and favourable changes in lipid parameters.
Notably, fasting glucose decreased by 9.08 mg/dL with Metaberine®
compared with 1.36 mg/dL with placebo, while glucose exposure and peak glucose
levels also declined significantly. The study further reported a 29% increase
in fasting GLP-1 and 22% increase in postprandial GLP-1 with Metaberine®. Total
cholesterol and LDL-C also decreased, while HDL-C increased. The study reported
100% participant retention and no supplement-related adverse events during the
trial.
“The publication of this clinical study marks an important milestone
for Metaberine® and for our efforts to develop next-generation metabolic health
solutions. The findings demonstrate that bio-optimised berberine can deliver
meaningful metabolic benefits at just 200 mg per day, addressing one of the key
limitations associated with conventional berberine formulations, high dosage
requirements,” said Dr. Arunkanth Krishnakumar,
Co-founder and CEO, Zeus Hygia Lifesciences.
Berberine has been widely studied for its role in glucose and lipid
metabolism, but conventional formulations are limited by poor bioavailability
and the need for substantially higher daily doses. Metaberine® uses Zeus
Hygia’s BioSOLVE® Technology, a proprietary aqueous processing technology
designed to enhance solubility and bioavailability, enabling a lower-dose
formulation.
The findings support the potential of Metaberine® as a functional
nutritional ingredient for metabolic wellness, particularly as demand grows for
accessible and effective solutions supporting healthy glucose and lipid
metabolism. The authors conclude that the results warrant further investigation
of bio-optimised berberine in metabolic health applications.
Metaberine® is available for B2B applications across nutraceuticals,
dietary supplements, functional foods and beverages, OTC health products,
pharmaceuticals, and contract manufacturing, enabling partners to develop
next-generation metabolic wellness solutions.
The study is available in the International Journal of Clinical
Trials:
https://www.ijclinicaltrials.com/index.php/ijct/article/view/1028?utm_source
Website: https://www.zeushygia.com/